Sunday, August 17, 2025
  • Advertise
  • Recruitment
  • Contact us:
  • Register
Irish Pharmacy News
  • News
    • Latest
    • Community Pharmacy
  • Learning
    • CPD
    • Features
    • Team Training
    • Research
  • Magazines
  • OTC
    • OTC Awards
    • Product News
  • Awards
    • Irish Pharmacy Awards 2024
    • Awards News
  • HPN
  • Log In
  • Register
No Result
View All Result
  • News
    • Latest
    • Community Pharmacy
  • Learning
    • CPD
    • Features
    • Team Training
    • Research
  • Magazines
  • OTC
    • OTC Awards
    • Product News
  • Awards
    • Irish Pharmacy Awards 2024
    • Awards News
  • HPN
  • Log In
  • Register
No Result
View All Result
Irish Pharmacy News

Lipertance will be available for prescription from November 2021.

Robyn Maginnis by Robyn Maginnis
10 December 2021
in Latest, Product News
0
Lipertance will be available for prescription from November 2021.

Servier Laboratories (Ireland) Ltd is delighted to announce that Lipertance, the combination of atorvastatin, perindopril and amlodipine1, will be available for prescription from November 2021 and is listed as a PCRS reimbursable product.

Lipertance® is the first Statin + ACEi + Calcium Channel blocker combination available in Ireland2.

Servier continue to add to their range of Single Pill Combination solutions for the management of patients with cardiovascular disease3. The arrival of Lipertance, in particular, offers greater intensification of blood pressure (BP) control for patients on a statin1. It follows the recent launch (Feb 2021) of , Lipercosyl the statin/ACEi combination of atorvastatin and perindopril4.

Like Lipercosyl®, Lipertance® controls high cholesterol and hypertension in unison1, helping patients with these cardiovascular risk factors to meet their target blood pressure5 and low-density lipoprotein cholesterol (LDL-C)6  and thereby helping to avoid cardiovascular outcomes1.

Atorvastatin has been shown to reduce concentrations of LDL-C by up to 49%7. Perindopril and amlodipine reduce BP by up to 33.7/17.1mmHg helping patients reach lower targets8. Perindopril and amlodipine’s antihypertensive effect is sustained for at least 24 hours and atorvastatin is a long-acting statin, ensuring true 24hr control from a single daily dose1, 9.

Furthermore, it has been demonstrated in the large ASCOT study (n=19,259 patients) that a combination of statin with amlodipine +/- perindopril yields a 53% relative risk reduction in fatal coronary events and non-fatal MI p<0.00011.

Prescribing the 3 agents in a Single-Pill Combination offers patients better efficacy, tolerability and adherence10-13.  Lipertance is taken one tablet daily in the morning before breakfast.1

Lipertance® is indicated for the treatment of essential hypertension and/or stable coronary artery disease, in association with primary hypercholesterolaemia or mixed hyperlipidaemia, as substitution therapy in adult patients adequately controlled with atorvastatin, perindopril and amlodipine given concurrently at the same dose level as in the combination. 1

Should you require any further information, please contact Servier on 01 6638110, or refer to the full Summary of Product Characteristics on www.medicines.ie

Lipertance 10mg/5mg/5mg film-coated tablets: €9.58

Lipertance 20mg/5mg/5mg film-coated tablets: €10.58

Lipertance 20mg/10mg/5mg film-coated tablets: €13.86

Lipertance 20mg/10mg/10mg film-coated tablets: €14.76

Lipertance 40mg/10mg/10mg film-coated tablets: €16.26

Background information:

Cardiovascular disease (CVD) remains the leading cause of death in Ireland14, and high serum cholesterol is an important modifiable risk factor for the development of CVD15. A new approach to the prevention of cardiovascular disease shows that the earlier and the longer BP and LDL-C are controlled, the greater the reduction in cardiovascular events16. Recent data published from the TILDA study (The Irish Longitudinal Study on Ageing) reports that the most common co-morbidities are hypertension and high cholesterol. Over 50% of the people who have hypertension also have high cholesterol17.

About Servier:

Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 150 countries and a turnover of 4.7 billion euros in 2020, Servier employs 22 500 people worldwide. Entirely independent, the Group reinvests in average 23% of its turnover (excluding generics) every year in research and development and uses all its profits for development. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neurodegenerative diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development.

More information: www.servier.ie

Previous Post

2021 CPD Modules – Community Pharmacy

Next Post

Urinary Incontinence in Pharmacy

Next Post
Urinary Incontinence in Pharmacy

Urinary Incontinence in Pharmacy

Supporting Enhanced Price Transparency in Pharmacies

Supporting Enhanced Price Transparency in Pharmacies

13 August 2025
Has women’s health in Ireland improved? Category Report: Women’s Health

Has women’s health in Ireland improved? Category Report: Women’s Health

13 August 2025
RCSI programme reaches over 17,000 Irish teens combating sexual health misinformation

RCSI programme reaches over 17,000 Irish teens combating sexual health misinformation

12 August 2025

RECOMMENDED NEWS

‘Rights group spearheads effort to combat stigma and discrimination in media reporting on HIV.’

‘Rights group spearheads effort to combat stigma and discrimination in media reporting on HIV.’

4 years ago
TWO OUT OF THREE PEOPLE IN IRELAND FEEL STRESSED AT LEAST ONCE A WEEK

TWO OUT OF THREE PEOPLE IN IRELAND FEEL STRESSED AT LEAST ONCE A WEEK

9 months ago

Uniphar Training & Development Award 2024

1 year ago
Revive Active won the Best Irish Pharmacy Brand category for 2020.

Revive Active won the Best Irish Pharmacy Brand category for 2020.

5 years ago
Tweets by Irish_PharmNews

Quick links

  • About
  • Advertise
  • Careers
  • Contact us

Other info

  • Contact us
  • Register for Digital Magazines
  • Privacy Policy
  • About
  • Advertise
  • Careers
  • Contact us

© 2024 IPN

  • Login

    Forgot password? | Register

    Register

    Registration confirmation will be emailed to you.

    Login | Forgot password?

    Reset Password

    Please enter your username or email address. You will receive a link to create a new password via email.

    Login

Login

Register

Forgotten Password?

Register | Lost your password?
| Back to Login
No Result
View All Result
  • News
  • Learning
  • Other
    • Conferencing
    • Developments
    • Product News
    • Profiles
    • Research
  • Digital Magazines (IPN Online Issues Older Issue Tabs)
  • Awards

© 2024 IPN